Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 07:16 AM
November 2025
Learn how to evaluate and manage patients with MASLD, MASH, and MetALD in this educational session led by Melissa Franco, PA-C, from the University of Miami. Using a real-world case, Melissa reviews how to identify metabolic-dysfunction–associated steatotic liver disease, distinguish it from alcohol-associated liver injury, and apply non-invasive testing tools such as FIB-4 and transient elastography to stratify fibrosis risk. The presentation explores how alcohol intake, metabolic risk factors, and obesity interact to accelerate liver inflammation and fibrosis, and discusses objective biomarkers like PEth testing to detect alcohol use. Viewers will gain practical insight into risk assessment, lifestyle modification, and management strategies for patients with combined metabolic and alcohol-related liver disease. For more hepatology education and resources, visit the GHAPP MASLD & MASH Community Network.
Related Webcast
Webcast: Comparing F3 and F4 Fibrosis With Oyin Penny
August 2025
Understanding the differences between F3 and F4 fibrosis is crucial in the management of MASH (Metabolic Associated Steatohepatitis) and other liver diseases. In this session with Oyin Penny, FNP, from the GHAPP MASLD Community Network, we explore a case-based comparison using non-invasive tests (NITs), including FibroScan, ELF score, and Fib-4, to highlight how staging impacts prognosis, treatment strategies, and long-term outcomes. Case 6A focuses on a patient with F3 fibrosis, discussing lifestyle modification, metabolic disease optimization, and the role of therapies like Resmetirom (Rezdiffra). Case 6B revisits the same patient profile but with F4 fibrosis, emphasizing advanced management including HCC surveillance, EGD screening for varices, and consideration of non-selective beta blockers. By contrasting these scenarios, this presentation underscores the importance of accurate fibrosis staging, risk stratification, and timely interventions to improve patient outcomes.
Watch Now
Webcast: Non-Invasive Testing With Jeremy Davis
September 2025
Join Jeremy Davis, NP, for a clear, clinic-ready walkthrough of non-invasive testing for MASLD/MASH. Using a real case, Jeremy shows how to risk-stratify patients starting with FIB-4 and when intermediate scores should trigger liver stiffness measurement. Learn practical cutoffs, image-quality checkpoints (valid measures, IQR/median), and common confounders (ALT/AST flares, cholestasis, recent meals, alcohol, obesity, ascites) that can overestimate stiffness. He contrasts pros/cons of VCTE vs. MRE, explains how to pair ELF with FibroScan, and maps decisions to AGA/AASLD-aligned pathways—who to refer, who to monitor, and how often to re-stage. The session closes with actionable counseling on lifestyle, weight loss targets, and cardiometabolic risk control to slow fibrosis progression while minimizing unnecessary biopsies.
Watch Now
Webcast: Non-Invasive Testing With Elizabeth Alqueza
August 2025
In this session, Elizabeth Alqueza, PA-C at Beth Israel Deaconess Medical Center, provides a comprehensive overview of non-invasive testing in patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MASH. Using a real clinical case, she explains how to evaluate patients with abnormal liver enzymes and steatosis on imaging, and how to apply widely used tools such as the FIB-4 score, ELF test, FibroScan (VCTE), CAP score, shear wave elastography, and MR elastography. Elizabeth highlights the strengths, limitations, and interpretation of each test, along with practical considerations like cost, accessibility, patient factors, and operator experience. She also reviews the MASLD care pathway, emphasizing how accurate staging with non-invasive tests helps identify at-risk patients with advanced fibrosis who need closer monitoring, lifestyle interventions, and specialty referral. This talk underscores the critical role of non-invasive assessment in preventing progression to cirrhosis, liver failure, and hepatocellular carcinoma.
Watch Now
Webcast: MASLD Pharmacotherapy With Allison Moser
November 2025
Join Allison Moser, NP, hepatology nurse practitioner at Rush University Medical Center, for a comprehensive update on pharmacotherapy in MASLD and MASH. In this MASLD Community Network session, Allison reviews the evolving treatment landscape—from lifestyle and metabolic management to the latest FDA-approved medications. Learn how resmetirom, the first and only approved therapy for MASH with stage 2–3 fibrosis, works as a thyroid hormone receptor-β agonist to improve liver fat and fibrosis. Discover the growing role of GLP-1 receptor agonists such as semaglutide in MASH management, as well as key insights on vitamin E, pioglitazone, and metabolic risk reduction through diet, exercise, and comorbidity control. This evidence-based discussion highlights the latest clinical trial data, practice guidelines, and real-world considerations for advanced practice providers managing metabolic liver disease. #MASH #MASLD #LiverHealth #Hepatology #APPeducation #Resmetirom #Semaglutide #FattyLiverDisease #NASH #MetabolicHealth
Watch Now
Webcast: Lifestyle Management With Allysa Saggese
August 2025
Join Allysa Saggese, NP, from Weill Cornell Medicine in New York City, for an insightful and practical discussion on lifestyle management for MASLD and MASH, presented through the GHAPP MASLD/MASH Community Network, sponsored by Madrigal Pharmaceuticals. In this case-based presentation, Allysa walks viewers through the non-pharmacologic strategies used to manage Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), highlighting the role of nutrition, physical activity, and patient-centered counseling. Using a real-world example of a 65-year-old patient with obesity, diabetes, and steatosis, Allysa demonstrates how to assess fibrosis risk through non-invasive testing like FIB-4 and FibroScan, and explains how lifestyle modifications remain central to slowing disease progression—even in the era of advanced therapeutics. The session explores the importance of motivational interviewing, cultural dietary preferences, and how to structure effective, individualized conversations around reducing sugar intake, increasing movement at home, and achieving sustainable 5–10% weight loss to improve liver histology. Allysa also breaks down the metabolic interplay between central adiposity, insulin resistance, and liver inflammation, and shares counseling tips to build patient trust and long-term engagement. Whether you're a GI or hepatology provider, this session delivers real-world guidance to help empower patients to reverse early liver damage through everyday lifestyle changes.
Watch Now
Webcast: MASLD vs MetALD With Valerie Shin
September 2025
Valerie Shin, NP from UCLA Health’s Pfleger Liver Institute, hosts a clear, practical overview of MASLD, MASH, and mixed-etiology MET-ALD for the GHAPP MASLD Community Network (sponsored by Madrigal). Through a common patient case, she explains how to recognize steatotic liver disease, why getting an accurate alcohol history matters, and how non-invasive tools (like FibroScan and alcohol biomarkers) help confirm what’s driving liver injury. You’ll hear straightforward guidance on counseling patients: heart-healthy/Mediterranean-style eating, sustainable weight loss, regular aerobic and resistance exercise, and complete alcohol cessation—plus when to consider specialty referral and ongoing surveillance. Perfect for APPs and GI clinicians seeking a simple, patient-centered approach to preventing progression from fatty liver to advanced disease.
Watch Now
Webcast: MASLD vs MetALD With Oyin Penny
October 2025
In this educational session, Oyin Penny, FNP, from Premier Gastroenterology of Kansas City, discusses the overlap between MASLD and MetALD, highlighting how metabolic risk factors and alcohol intake accelerate liver injury and fibrosis. Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this talk uses a real-world case study to explain diagnostic tools like FibroScan, CAP score, and PEth testing, along with clinical criteria for distinguishing MASLD, MetALD, and ALD. Key management strategies include Mediterranean diet, weight loss, alcohol abstinence, and monitoring for advanced fibrosis and HCC risk.
Watch Now
Webcast: MASLD Basics With Scott Springer
August 2025
Welcome to the GHAPP MASLD Community Network, where Scott Springer, PA-C, from Erie County Medical Center in Buffalo, NY, provides a comprehensive overview of the evolving landscape of steatotic liver disease. Sponsored by Madrigal Pharmaceuticals, this session breaks down the recent nomenclature shift from NAFLD/NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). Scott explores how overlapping etiologies like alcohol-associated liver disease (ALD) and the emerging classification of MetALD better reflect real-world patient populations. Learn about key diagnostic strategies—including the use of FIB-4, ELF score, and transient elastography—to assess fibrosis risk and guide referral to hepatology care. With a clinical case study, Scott highlights the importance of accurate staging, ruling out alternative etiologies, and understanding progression rates in high-risk patients. This session is a must-watch for GI and hepatology APPs looking to stay updated on guidelines, non-invasive diagnostics, and best practices for managing MASLD/MASH in primary and specialty settings.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis with Sarah Dawkins
September 2025
In this educational session from the MASLD Community Network, Sarah Dawkins, NP, from Duke University Medical Center, explores the critical differences between F3 and F4 fibrosis in patients with MASLD and MASH. Through real patient case studies, she highlights how non-invasive testing methods—such as FIB-4, FibroScan, ELF testing, and imaging—play a vital role in accurately staging fibrosis and guiding treatment decisions. The discussion also covers the impact of metabolic risk factors like type 2 diabetes, obesity, and hypertension, along with strategies for management that include lifestyle modifications, weight loss goals, GLP-1 therapy, and the use of resmetirom (Rezdiffra) for eligible patients. Sarah emphasizes the importance of HCC surveillance, esophageal varices screening, and ongoing monitoring to improve outcomes for patients with advanced liver disease. This session underscores why distinguishing between F3 and F4 fibrosis is essential in clinical practice and how non-invasive testing can support timely diagnosis, treatment, and long-term care planning.
Watch Now
Webcast: MASLD vs MetALD With HoChong Gilles
November 2025
In this session from the GHAPP MASLD Community Network, supported by Madrigal Pharmaceuticals, hepatology expert HoChong Gilles, DNP, from the Richmond VA Medical Center, explores the evolving understanding of MetALD (Metabolic dysfunction-associated Alcohol-related Liver Disease). Through a detailed case study, Gilles examines how metabolic risk factors and alcohol intake intersect to drive fibrosis progression, highlighting diagnostic tools such as FibroScan, biomarkers like PEth, and key distinctions between MASLD, MASH, and alcohol-predominant liver disease. This presentation underscores the importance of assessing true alcohol exposure, utilizing noninvasive testing, and integrating lifestyle interventions for improved liver and metabolic outcomes.
Watch Now